Ardelyx offers 28% revenue growth and a forward P/E of 11.0x with roughly 21-to-1 favorable risk/reward and 150% upside to analyst targets, yet business quality sitting just below the minimum floor constrains the position recommendation to avoid until quality metrics recover.
Thesis pillars
- Quality Below Minimum Floor→Stable
- Compelling Valuation Outsized Asymmetry→Stable
- Strong Revenue Growth Trajectory→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 19, 2026
Ardelyx, Inc. (ARDX) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $3.10 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: IBSRELA; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0).
Ardelyx is a commercial-stage biopharmaceutical company marketing two FDA-approved tenapanor-based therapies: IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adult chronic kidney disease dialysis patients. The company says it... Read more
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $3.10 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: IBSRELA; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: Death cross but MACD improving, RSI 42. Score 6.2/10, moderate confidence.
Passes 3/8 gates (clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: speculative.
About Ardelyx, Inc.
About Ardelyx, Inc.
Ardelyx markets two FDA-approved tenapanor therapies, IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adult dialysis patients, and says it is substantially dependent on IBSRELA's continued commercialization. As of December 31, 2025, the company held $264.7 million in cash, cash equivalents, and short-term investments against a $946.9 million accumulated deficit, funded partly through a $300.0 million SLR loan facility with $200.0 million drawn.
Ardelyx earns revenue from direct U.S. sales of IBSRELA and XPHOZAH plus upfront payments, development and sales milestones, and royalties from ex-U.S. licensees Knight (Canada), Kyowa Kirin (Japan, marketed as PHOZEVEL), and Fosun Pharma (China), for which Ardelyx also supplies drug substance or finished product under separate supply agreements. Both products rely on third-party contract manufacturers for API and finished dosage forms rather than in-house production. IBSRELA competes against branded secretagogues Linzess and Trulance plus generic lubiprostone in a roughly 13-million-patient IBS-C market, while XPHOZAH competes against six generic phosphate binders and faces a structural headwind: the January 1, 2025 shift of XPHOZAH into the ESRD Prospective Payment System eliminated its separate Medicare Part D coverage, a change Ardelyx says had a negative and material impact on 2025 XPHOZAH revenue even as patient counts grew. The company is also advancing a Phase 3 trial of tenapanor in chronic idiopathic constipation and an early-stage next-generation NHE3 inhibitor, RDX10531.
Show full overview
Ardelyx's core intellectual property protecting tenapanor combines a composition-of-matter patent (U.S. 8,541,448) extended under the Hatch-Waxman Act to August 1, 2033, with method-of-use patents covering phosphorus control expiring around April 2034 and a newly issued formulation patent (U.S. 12,539,299, issued January 22, 2026) covering the commercial IBSRELA and XPHOZAH formulations that runs until November 26, 2042. That formulation patent could give Ardelyx a decade of additional exclusivity beyond the composition patent's 2033 expiration, but its value depends on whether generic challengers can design around the specific formulation claims rather than the underlying tenapanor molecule, a test that has not yet been litigated.
See also: Healthcare · Biotechnology
From Ardelyx, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Ardelyx, Inc.
Latest news
- NEWS Ardelyx Presents Real-World Data at ASN Kidney Week 2026 for XPHOZAH — fiscal.ai Oct 24, 2026 positive
- NEWS Ardelyx Reports Real-World Phosphate Reductions With XPHOZAH Across Phosphate Binder Groups In Dialysis Patients, Presen — benzinga Oct 23, 2026 positive
- NEWS Ardelyx to Host Third Quarter 2026 Financial Results Conference Call — fiscal.ai Oct 20, 2026 neutral
- NEWS Wedbush Adjusts Price Target on Ardelyx to $8 — fiscal.ai Oct 19, 2026 neutral
- NEWS Ardelyx Presents Real-World Data Showing Significant Reduction In GI-Related Healthcare Resource Utilization After IBSRE — benzinga Oct 12, 2026 positive
Generated 2026-10-29T11:48:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductIBSRELA10-K Item 1A: 'We are substantially dependent on the successful commercialization of IBSRELA, and there is no guarantee that we will maintain sufficient market acceptance for IBSRELA'
Material Events(8-K, last 90d)
- 2026-06-17Item 5.02LOWBoard approved a second amendment to the 2014 Equity Incentive Award Plan on April 16, 2026, subsequently ratified by stockholders at the June 16, 2026 annual meeting; routine equity plan amendment.SEC filing →
- 2026-06-17Item 5.07LOWAt the June 16, 2026 annual meeting, stockholders voted on matters including the Equity Plan Amendment; 247,029,387 shares were entitled to vote as of the April 22, 2026 record date.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $3.10 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: IBSRELA; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: Death cross but MACD improving, RSI 42. Prior stop was $2.88. Score 6.2/10, moderate confidence.
Resistance target: $3.39 (+9.4% upside). Prior stop was $2.88. Stop-loss: $2.88.
Concentration risk — Product: IBSRELA; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0); Leverage penalty (D/E 1.9): -1.0.
Ardelyx, Inc. trades at a P/E of N/A (forward 10.7). TrendMatrix value score: 9.4/10. Verdict: Sell.
17 analysts cover ARDX with a consensus score of 4.5/5. Average price target: $13.
What does Ardelyx, Inc. do?Ardelyx is a commercial-stage biopharmaceutical company marketing two FDA-approved tenapanor-based therapies: IBSRELA...
Ardelyx is a commercial-stage biopharmaceutical company marketing two FDA-approved tenapanor-based therapies: IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adult chronic kidney disease dialysis patients. The company says it is substantially dependent on IBSRELA's continued commercialization, held a $946.9 million accumulated deficit as of December 31, 2025, and licenses tenapanor to partners including Knight (Canada), Kyowa Kirin (Japan), and Fosun Pharma (China) for royalties and product-supply revenue.